Lantern Pharma Inc.
NASDAQ:LTRN
Lantern Pharma Inc.
Free Cash Flow
Lantern Pharma Inc.
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lantern Pharma Inc.
NASDAQ:LTRN
|
Free Cash Flow
-$14.4m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-62%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Free Cash Flow
$17.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
20%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Free Cash Flow
$10.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Free Cash Flow
$10.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Free Cash Flow
-$978m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-5%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Free Cash Flow
$3.5B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
24%
|
|
Lantern Pharma Inc.
Glance View
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2020-06-11. The firm is focused on leveraging artificial intelligence (AI), machine learning and genomic data to streamline the drug development process and to identify the patients, which benefits from its targeted oncology therapies. The Company’s therapies portfolio consists of small molecule drug candidates and new compounds, which it is developing with the assistance of its AI platform and its biomarker driven approach. The Company’s AI platform, RADR uses big data analytics, including combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data, and machine learning. The Company’s data-driven, gnomically targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy, which identifies, rescues or develops, and advances potential small molecule drug candidates.
See Also
What is Lantern Pharma Inc.'s Free Cash Flow?
Free Cash Flow
-14.4m
USD
Based on the financial report for Dec 31, 2023, Lantern Pharma Inc.'s Free Cash Flow amounts to -14.4m USD.
What is Lantern Pharma Inc.'s Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-62%
Over the last year, the Free Cash Flow growth was -12%. The average annual Free Cash Flow growth rates for Lantern Pharma Inc. have been -36% over the past three years , -62% over the past five years .
You don't have any saved screeners yet